AZD 4721

Drug Profile

AZD 4721

Alternative Names: AZD4721

Latest Information Update: 28 Aug 2014

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antibronchitics
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Jul 2014 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (PO)
  • 01 Jun 2014 AstraZeneca completes a phase I trial in Chronic obstructive pulmonary disease (in volunteers) in United Kingdom (NCT01962935)
  • 31 Dec 2013 AstraZeneca completes a phase I trial in Healthy volunteers in United Kingdom (NCT01889160)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top